

Laquinimod

Catalog No: tcsc0839



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 500mg



Specifications

CAS No:

248281-84-7

Formula:

$C_{19}H_{17}ClN_2O_3$

Pathway:

NF-κB

Target:

NF-κB

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

ABR-215062

Observed Molecular Weight:

356.8


Product Description

Laquinimod is a potent immunomodulator; reduces NF-κB activation in astrocytic.

IC50 & Target: NF-κB^[3]

In Vitro: Laquinimod reverses EAE and inhibits pathogenic T cell immune responses. Laquinimod reverses RR-EAE and inhibits inflammatory T cell responses via a direct effect on myeloid APC. Laquinimod alters myeloid APC subsets and inhibits Th1 and Th17 polarization of myelin-specific T cells. Laquinimod-induced type II (M2) monocytes reverse established EAE^[1]. Laquinimod modulates the phenotype of B cells of healthy donors. Laquinimod modulates expression of markers related to regulatory capacity in B cells of RRMS patients. Laquinimod reduces IFNγ cytokine expression in CD4⁺ T cells^[2].

In Vivo: Laquinimod treatment inhibits donor myelin-specific T cells from transferring EAE to naive recipient mice. In vivo laquinimod treatment alters subpopulations of myeloid antigen presenting cells (APC) that include a decrease in CD11c⁺CD11b⁺CD4⁺ dendritic cells (DC) and an elevation of CD11b^{hi}Gr1^{hi} monocytes^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!